41,356 Shares in RxSight, Inc. (NASDAQ:RXST) Acquired by Algert Global LLC

Algert Global LLC acquired a new stake in shares of RxSight, Inc. (NASDAQ:RXST) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 41,356 shares of the company’s stock, valued at approximately $2,488,000. Algert Global LLC owned 0.11% of RxSight at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. CWM LLC lifted its position in RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the period. Quest Partners LLC purchased a new stake in shares of RxSight in the second quarter worth about $41,000. Larson Financial Group LLC acquired a new stake in RxSight during the first quarter worth about $51,000. Amalgamated Bank raised its position in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after acquiring an additional 207 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in RxSight in the second quarter valued at approximately $156,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Ilya Goldshleger sold 9,000 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.25, for a total value of $353,250.00. Following the completion of the sale, the insider now directly owns 42,246 shares in the company, valued at $1,658,155.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 21,405 shares of company stock valued at $986,423 in the last 90 days. 9.36% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on RXST. BTIG Research raised their price objective on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus cut their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Wells Fargo & Company lowered their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $60.14.

RxSight Trading Down 4.6 %

Shares of RxSight stock opened at $47.15 on Wednesday. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The firm’s 50-day moving average price is $51.16 and its 200 day moving average price is $53.90. The firm has a market capitalization of $1.74 billion, a PE ratio of -37.42 and a beta of 1.22.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The business’s revenue was up 67.6% on a year-over-year basis. On average, sell-side analysts predict that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.